[go: up one dir, main page]

ECSP14024526A - Derivados bicíclicos de pirazinona - Google Patents

Derivados bicíclicos de pirazinona

Info

Publication number
ECSP14024526A
ECSP14024526A ECIEPI201424526A ECPI201424526A ECSP14024526A EC SP14024526 A ECSP14024526 A EC SP14024526A EC IEPI201424526 A ECIEPI201424526 A EC IEPI201424526A EC PI201424526 A ECPI201424526 A EC PI201424526A EC SP14024526 A ECSP14024526 A EC SP14024526A
Authority
EC
Ecuador
Prior art keywords
pirazinone
bicyclic derivatives
diseases
tankirase
inflammation
Prior art date
Application number
ECIEPI201424526A
Other languages
English (en)
Inventor
Ansgar Wegener
Gérard Moinet
Hans Peter Buchstaller
Dieter Dorsch
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14024526(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP14024526A publication Critical patent/ECSP14024526A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de la fórmula I (ver archivo de imágenes) en donde R1, X e Y tienen los significados indicados en la reivindicación 1, son inhibidores de Tankirasa y se pueden emplear, inter alia, para el tratamiento de enfermedades tales como cáncer, enfermedades cardiovasculares, lesión del sistema nervioso central y diferentes formas de inflamación.
ECIEPI201424526A 2012-03-28 2014-10-27 Derivados bicíclicos de pirazinona ECSP14024526A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12002215 2012-03-28

Publications (1)

Publication Number Publication Date
ECSP14024526A true ECSP14024526A (es) 2015-09-30

Family

ID=48013911

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201424526A ECSP14024526A (es) 2012-03-28 2014-10-27 Derivados bicíclicos de pirazinona

Country Status (32)

Country Link
US (1) US9120805B2 (es)
EP (1) EP2831077B1 (es)
JP (1) JP6096879B2 (es)
KR (1) KR102070567B1 (es)
CN (1) CN104169284B (es)
AR (1) AR090496A1 (es)
AU (1) AU2013242492B2 (es)
CA (1) CA2868620C (es)
CL (1) CL2014002557A1 (es)
CO (1) CO7111292A2 (es)
DK (1) DK2831077T3 (es)
EA (1) EA027416B1 (es)
EC (1) ECSP14024526A (es)
ES (1) ES2585044T3 (es)
HK (1) HK1203961A1 (es)
HR (1) HRP20160908T1 (es)
HU (1) HUE030067T2 (es)
IL (1) IL234713A (es)
MX (1) MX351149B (es)
MY (1) MY172308A (es)
NZ (1) NZ630489A (es)
PE (1) PE20142186A1 (es)
PH (1) PH12014501829A1 (es)
PL (1) PL2831077T3 (es)
PT (1) PT2831077T (es)
RS (1) RS54997B1 (es)
SG (1) SG11201405750YA (es)
SI (1) SI2831077T1 (es)
TW (1) TWI576346B (es)
UA (1) UA112795C2 (es)
WO (1) WO2013143663A1 (es)
ZA (1) ZA201407828B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193689B2 (en) 2012-03-07 2015-11-24 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
RS54997B1 (sr) 2012-03-28 2016-11-30 Merck Patent Gmbh Biciklični pirazinon derivati
BR112014032053A2 (pt) * 2012-06-20 2017-06-27 Hoffmann La Roche composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
CN105722835B (zh) 2013-09-11 2018-07-31 癌症研究协会:皇家癌症医院 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用
HUE037606T2 (hu) * 2013-12-23 2018-09-28 Merck Patent Gmbh Imidazopirazinon-származékok
KR101739003B1 (ko) 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
ES2865483T3 (es) 2014-12-05 2021-10-15 Celgene Corp Pirazolo[1,5-a]pirazinas sustituidas en 4,6 como inhibidores de Janus cinasa
BR112018002465A2 (pt) 2015-08-17 2018-09-18 Lupin Ltd derivados de heteroarila como inibidores de parp
WO2017144995A1 (en) 2016-02-24 2017-08-31 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
JP2021523910A (ja) 2018-05-17 2021-09-09 バイエル・アクチエンゲゼルシヤフト 置換されたジヒドロピラゾロピラジンカルボキサミド誘導体
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds
GB2632441A (en) * 2023-08-08 2025-02-12 Duke Street Bio Ltd Deuterated PARP1 inhibitor compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE237596T1 (de) 1996-02-13 2003-05-15 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
WO2007138355A1 (en) * 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
JP5496680B2 (ja) * 2006-12-28 2014-05-21 アッヴィ・インコーポレイテッド ポリ（ａｄｐ−リボース）ポリメラーゼの阻害剤
CA2678248C (en) 2007-03-08 2016-06-28 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
WO2009130231A1 (en) 2008-04-24 2009-10-29 Glaxo Group Limited Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
WO2009130232A1 (en) 2008-04-24 2009-10-29 Glaxo Group Limited Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
WO2010043676A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
US8450320B2 (en) * 2010-04-16 2013-05-28 Abbvie Inc. Pyrrolopyrazinone inhibitors of kinases
CN102229611B (zh) * 2011-04-26 2012-12-12 山东大学 2,6-二芳基吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其应用
RS54997B1 (sr) 2012-03-28 2016-11-30 Merck Patent Gmbh Biciklični pirazinon derivati
BR112014032053A2 (pt) * 2012-06-20 2017-06-27 Hoffmann La Roche composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção

Also Published As

Publication number Publication date
HK1203961A1 (en) 2015-11-06
PH12014501829B1 (en) 2014-11-10
WO2013143663A1 (en) 2013-10-03
CO7111292A2 (es) 2014-11-10
MX2014011420A (es) 2014-11-25
CA2868620A1 (en) 2013-10-03
KR20140140099A (ko) 2014-12-08
DK2831077T3 (en) 2016-08-15
HUE030067T2 (en) 2017-04-28
EA201401062A1 (ru) 2015-04-30
JP6096879B2 (ja) 2017-03-15
ZA201407828B (en) 2015-12-23
AU2013242492A1 (en) 2014-11-13
CL2014002557A1 (es) 2014-12-19
PL2831077T3 (pl) 2016-10-31
RS54997B1 (sr) 2016-11-30
UA112795C2 (uk) 2016-10-25
CA2868620C (en) 2020-02-25
CN104169284B (zh) 2017-03-29
MY172308A (en) 2019-11-21
AR090496A1 (es) 2014-11-19
TW201343650A (zh) 2013-11-01
IL234713A (en) 2016-09-29
CN104169284A (zh) 2014-11-26
MX351149B (es) 2017-10-04
KR102070567B1 (ko) 2020-01-29
ES2585044T3 (es) 2016-10-03
PH12014501829A1 (en) 2014-11-10
PT2831077T (pt) 2016-08-12
HRP20160908T1 (hr) 2016-09-23
EA027416B1 (ru) 2017-07-31
NZ630489A (en) 2016-04-29
PE20142186A1 (es) 2014-12-29
EP2831077A1 (en) 2015-02-04
SI2831077T1 (sl) 2016-09-30
SG11201405750YA (en) 2014-10-30
JP2015511609A (ja) 2015-04-20
US20150057264A1 (en) 2015-02-26
AU2013242492B2 (en) 2016-12-15
EP2831077B1 (en) 2016-04-27
TWI576346B (zh) 2017-04-01
US9120805B2 (en) 2015-09-01

Similar Documents

Publication Publication Date Title
ECSP14024526A (es) Derivados bicíclicos de pirazinona
ECSP14017586A (es) Derivados de tetrahidro-quinazolinona
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
GT201500051A (es) Inhibidores de glucosilceramida sintasa
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX2017014375A (es) Moduladores del ccr2.
CL2017000290A1 (es) Inhibidores de la proteína kinasa c y métodos de su uso.
MX377384B (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
EA201500314A1 (ru) Лекарственные формы энзалутамида
CR20150316A (es) Compuestos y sus métodos de empleo
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
UY33883A (es) Novedosos derivados heterocíclicos
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CL2014001993A1 (es) Uso de melatonina para el tratamiento de trastornos del ritmo circadiano
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
UY35142A (es) Derivados de triazolopirazinas como inhibidores de brd4
GT201500069A (es) Piridinonas bicìclicas novedosas
MX359656B (es) Derivados de oxoquinazolinil-butanamida.
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
MX2016014436A (es) Derivados de heterociclil-butanamida.
BR112016001978A2 (pt) derivados de ciclopentano 1,3-dissubstituído
MX364859B (es) Derivados de imidazopirazinona.
AR090085A1 (es) USO DE COMPUESTOS DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE GLUCOGENO SINTASA CINASA 3 b